Clinical trials: Melanoma Stage III
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Recurrent Melanoma, Stage IIB Melanoma (Locally Advanced)
Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery
This phase II trial studies how well giving dabrafenib alone and in combination with trametinib before surgery works in treating patients with advanced melanoma that can be removed by surgery.
- Conditions
- Recurrent Melanoma, Stage IIB Melanoma (Locally Advanced), Stage IIC Melanoma (Locally Advanced), Stage IIIA Melanoma
- Trial name
- NCT01701037
- Testing
- dabrafenib, trametinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Melanoma
A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma
A phase IIb, multicentre, open label study to evaluate the effectiveness, safety, and tolerability of intratumoural tigilanol tiglate in adult participants with Stage IIIB to IV M1c melanoma
- Trial name
- NCT05234437
- Testing
- tigilanol tiglate
- Where
- 3 sites in Australia
- Volunteers
- 1 people
- Sponsor
- QBiotics Group Limited
Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
This research study is studying a combination of two drugs that change the immune system and tumor as a possible treatment for metastatic or unresectable stage III or IV cutaneous melanoma.
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma, Unresectable Stage III Cutaneous Melanoma, Unresectable Stage IV Cutaneous Melanoma
- Trial name
- NCT04356729
- Testing
- Atezolizumab, Bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- F. Stephen Hodi, MD
Stages III Skin Melanoma, Stages II Skin Melanoma
Efficacy of Propranolol Treatment to Prevent Melanoma Progression
Melanoma's incidence is increasing worldwide. The efforts made in melanoma screening led to an earlier detection of the primary tumour and a better prognosis, but melanoma remains an aggressive cancer when it comes to its…
- Conditions
- Stages III Skin Melanoma, Stages II Skin Melanoma, Stage IB Skin Melanoma
- Trial name
- NCT01988831
- Testing
- Propranolol hydrochloride
- Where
- Switzerland
- Volunteers
- 450 people
- Sponsor
- University Hospital, Geneva
Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms
A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver
The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS) and Overall Survival(OS), achieved by HX008 Plus Transcatheter Arterial Chemoembolization (TACE) or Temozolomide…
- Trial name
- NCT05647954
- Testing
- HX008 + TACE, Temozolomide + TACE, Pembrolizumab
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Taizhou Hanzhong biomedical co. LTD
Malignant Melanoma, Recurrent Melanoma
Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma
This study evaluated two chemotherapy regimens with and without the addition of interferon in patients with advanced or recurrent melanoma.
- Trial name
- SICOG 0109 (NCT01359956)
- Testing
- Dacarbazine, Fotemustine, Interferon Alfa-2b
- Volunteers
- 269 people
- Sponsor
- National Cancer Institute, Naples
Melanoma Metastatic, Melanoma, Skin
Observational Study of Patients With Advanced Melanoma (Skin Cancer) to Assess if IOpener®-Melanoma Test Can Predict Response to Immunotherapy.
The goal of this observational study is to assess whether the IOpener® melanoma test can assist treating physicians in deciding which therapy is most suitable for patients with skin cancer (advanced cutaneous melanoma).
- Conditions
- Melanoma Metastatic, Melanoma, Skin, Melanoma Stage III or IV, Melanoma Advanced
- Trial name
- COMO (NCT06784778)
- Testing
- PBMC Kinase Activity Profile
- Where
- 3 sites in Germany
- Volunteers
- 196 people
- Sponsor
- Pamgene International B.V.
Intraocular Melanoma, Melanoma (Skin)
Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells.
- Trial name
- NCT00027742
- Testing
- pegylated interferon alfa, temozolomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Melanoma
Intratumoral Application of L19IL2 in Patients With Malignant Melanoma
Phase II, non-randomized, multicenter, prospective study designed to test the efficacy and safety of intratumorally administered L19IL2 in patients suffering from metastatic melanoma.
- Trial name
- NCT01253096
- Testing
- Intratumoral injections of L19IL2
- Where
- 3 sites in Austria, Germany
- Volunteers
- 25 people
- Sponsor
- Philogen S.p.A.
Stage III Skin Melanoma
Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients
This is a two-arm Phase 1b feasibility trial consisting of 20 patients receiving the combination of ipilimumab+nivolumab, either adjuvant, or split neo-adjuvant and adjuvant.
- Trial name
- OpACIN (NCT02437279)
- Testing
- Surgery of the tumor, Infusion with ipilimumab 3 mg/kg q3wks, Infusion with nivolumab 1 mg/kg q3wks
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- The Netherlands Cancer Institute
Uveal Melanoma
Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma
Patients suffering from uveal melanoma (typed positive for monosomy 3 and without evidence for metastases) will be vaccinated over a period of 2 years with Dendritic Cell loaded with autologous Tumor RNA.
- Trial name
- NCT01983748
- Testing
- Autologous Dendritic Cells loaded with autologous Tumor RNA
- Where
- 8 sites in Germany
- Volunteers
- 200 people
- Sponsor
- University Hospital Erlangen
Melanoma, Ovarian Cancer
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
The purpose of this study is to find out which way of giving high-dose radiation works best for treatment of cancer that has spread to bone, the spine, soft tissue, or lymph nodes.
- Conditions
- Melanoma, Ovarian Cancer, Sarcoma, Bone
- Trial name
- NCT01223248
- Testing
- IGIMRT using a single dose of 24 Gy, IGIMRT 27 Gy in 3 fractions
- Where
- 4 sites in United States, Italy and 1 more
- Volunteers
- 220 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Locally Advanced Melanoma, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients
This phase I/II trial tests the safety and side effects of LN-144 (Lifileucel) and pembrolizumab in treating patients with stage IIIB-D or stage IV melanoma that has spread to nearby tissue or lymph nodes.
- Conditions
- Locally Advanced Melanoma, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Trial name
- NCT05176470
- Testing
- Cyclophosphamide, Fludarabine, Lifileucel
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Richard Wu
Stage IV Melanoma, Stage III Melanoma
TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma
This phase 2 trial will investigate the efficacy and safety of trametinib and dabrafenib in patients with advanced BRAF V600 (v-Raf murine sarcoma viral oncogene homolog B) wild-type melanoma (stratified according to BRAF V600…
- Trial name
- TraMel-WT (NCT04059224)
- Testing
- Trametinib, Dabrafenib
- Where
- Belgium
- Volunteers
- 45 people
- Sponsor
- Universitair Ziekenhuis Brussel
Melanoma Stage Iv, Melanoma Stage Iii
Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain
This is an observational, multicentre epidemiological study with a longitudinal cohort in which information will be retrieved from medical records of patients with advanced metastatic or unresectable melanoma at first diagnosis.
- Conditions
- Melanoma Stage Iv, Melanoma Stage Iii, Advanced Cancer
- Trial name
- GEM-1801 (NCT03605771)
- Testing
- Daily Clinical Practice
- Where
- 39 sites in Spain
- Volunteers
- 400 people
- Sponsor
- Grupo Español Multidisciplinar de Melanoma
Cutaneous Melanoma, Mucosal Melanoma
Neoadjuvant and Adjuvant Checkpoint Blockade
This randomized phase II trial studies how well nivolumab with or without ipilimumab or relatlimab before surgery works in treating patients with stage IIIB-IV melanoma that can be removed by surgery.
- Conditions
- Cutaneous Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage III Acral Lentiginous Melanoma AJCC v7
- Trial name
- NCT02519322
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Melanoma
Study of gp75 Vaccine in Patients With Stage III and IV Melanoma
Up to 24 patients with stage III or stage IV melanoma will be enrolled. Patients who are currently disease-free but at high risk for relapse are also eligible. Patients will receive vaccinations of gp75 at assigned dose levels.
- Trial name
- NCT00034554
- Testing
- gp75 DNA vaccine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Eli Lilly and Company
Melanoma (Skin)
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not yet known whether treatment with interferon alfa is more effective than observation alone for stage II or stage III melanoma that has been…
- Trial name
- NCT00003641
- Testing
- interferon alfa-2b, observation
- Where
- 533 sites in United States, Australia and 2 more
- Volunteers
- 1,150 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Melanoma
A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
The purpose of this clinical research study is to evaluate the Best Overall Response Rate (BORR), (as per modified WHO criteria) in patients with previously treated melanoma-Stage III (unresectable) or Stage IV melanoma receiving…
- Trial name
- NCT00289627
- Testing
- ipilimumab (MDX-010, BMS-734016)
- Where
- 53 sites in United States, Austria and 8 more
- Volunteers
- 155 people
- Sponsor
- Bristol-Myers Squibb